SEARCH

SEARCH BY CITATION

References

  • 1
    Sadler JE, Mannucci PM, Berntorp E et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000; 84: 16074.
  • 2
    Biron C, Mahieu B, Rochette A et al. Preoperative screening for von Willebrand disease type 1: low yield and limited ability to predict bleeding. J Lab Clin Med 1999; 134: 6059.
  • 3
    Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand’s disease. Blood 1987; 69: 4549.
  • 4
    Werner EJ, Broxson EH, Tucker EL, Giroux DS, Shults J, Abshire TC. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr 1993; 123: 8938.
  • 5
    Hallberg L, Hogdahl AM, Nilsson L, Rybo G. Menstrual blood loss: a population study: variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand 1966; 45: 32051.
  • 6
    Association of Hemophilia Clinic Directors of Canada. Hemophilia and von Willebrand’s disease: 1. Diagnosis, comprehensive care and assessment. CMAJ 1995; 153: 1925.
  • 7
    Federici AB, Castaman G, Mannucci PM, Italian Association of Hemophilia Centers (AICE). Guidelines for the diagnosis and management of von Willebrand disease in Italy. Haemophilia 2002; 8: 60721.
  • 8
    Laffan M, Brown SA, Collins PW et al. The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors’ Organization. Haemophilia 2004; 10: 199217.
  • 9
    Pasi KJ, Collins PW, Keeling DM et al. Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors’ Organization. Haemophilia 2004; 10: 21831.
  • 10
    The National Heart, Lung, and Blood Institute. The Diagnosis, Evaluation and Management of Von Willebrand Disease. Bethesda, MD: National Heart, Lung, and Blood Institute, National Institutes of Health, 2007. Available at: http://www.nhlbi.nih.gov/guidelines/vwd (last accessed 07. 01. 2008).
  • 11
    Von Willebrand EA. Hereditary pseudohaemophilia. Haemophilia 1999; 5: 22331.
  • 12
    Montgomery RR, Gill JC. Interactions between von Willebrand factor and factor VIII: where did they first meet. J Pediatr Hematol Oncol 2000; 22: 26975.
  • 13
    Rosenberg JB, Greengard JS, Montgomery RR. Genetic induction of a releasable pool of factor VIII in human endothelial cells. Arterioscler Thromb Vasc Biol 2000; 20: 268995.
  • 14
    Miller CH, Haff E, Platt SJ et al. Measurement of von Willebrand factor activity: relative effects of ABO blood type and race. J Thromb Haemost 2003; 1: 21917.
  • 15
    Sukhu K, Poovalingam V, Mahomed R, Giangrande PL. Ethnic variation in von Willebrand factor levels can influence the diagnosis of von Willebrand disease. Clin Lab Haematol 2003; 25: 2479.
  • 16
    Ginsburg D, Handin RI, Bonthron DT et al. Human von Willebrand factor (vWF): isolation of complementary DNA (cDNA) clones and chromosomal localization. Science 1985; 228: 14016.
  • 17
    Mancuso DJ, Tuley EA, Westfield LA et al. Structure of the gene for human von Willebrand factor. J Biol Chem 1989; 264: 1951427.
  • 18
    Patracchini P, Calzolari E, Aiello V et al. Sublocalization of von Willebrand factor pseudogene to 22q11.22-q11.23 by in situ hybridization in a 46,X,t(X;22)(pter;q11.21) translocation. Hum Genet 1989; 83: 2646.
  • 19
    Mancuso DJ, Tuley EA, Westfield LA et al. Human von Willebrand factor gene and pseudogene: structural analysis and differentiation by polymerase chain reaction. Biochemistry 1991; 30: 25369.
  • 20
    Sadler JE. Von Willebrand factor. J Biol Chem 1991; 266: 2277780.
  • 21
    Eikenboom JC, Vink T, Briet E, Sixma JJ, Reitsma PH. Multiple substitutions in the von Willebrand factor gene that mimic the pseudogene sequence. Proc Natl Acad Sci USA 1994; 91: 22214.
  • 22
    Eikenboom JC, Castaman G, Vos HL, Bertina RM, Rodeghiero F. Characterization of the genetic defects in recessive type 1 and type 3 von Willebrand disease patients of Italian origin. Thromb Haemost 1998; 79: 70917.
  • 23
    Surdhar GK, Enayat MS, Lawson S, Williams MD, Hill FG. Homozygous gene conversion in von Willebrand factor gene as a cause of type 3 von Willebrand disease and predisposition to inhibitor development. Blood 2001; 98: 24850.
  • 24
    Ginsburg D, Sadler JE, Consortium on von Willebrand Factor Mutations and Polymorphisms, Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Von Willebrand disease: a database of point mutations, insertions, and deletions. Thromb Haemost 1993; 69: 17784.
  • 25
    Sadler JE, Ginsburg D, Consortium on von Willebrand Factor Mutations and Polymorphisms, Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. A database of polymorphisms in the von Willebrand factor gene and pseudogene. Thromb Haemost 1993; 69: 18591.
  • 26
    ISTH. SSC VWF Database [Database on the Internet]. Sheffield, UK: University of Sheffield. Available at: http://www.vwf.group.shef.ac.uk/index.html (last accessed 23.01.2008).
  • 27
    Sadler JE, Budde U, Eikenboom JC et al. Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand factor. J Thromb Haemost 2006; 4: 210314 (Epub 2 August 2006).
  • 28
    Sadler JE. Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. A revised classification of von Willebrand disease. Thromb Haemost 1994; 71: 5205.
  • 29
    Castaman G, Federici AB, Rodeghiero F, Mannucci PM. Von Willebrand’s disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. Haematologica 2003; 88: 94108.
  • 30
    Meyer D, Fressinaud E, Gaucher C et al. INSERM Network on Molecular Abnormalities in von Willebrand Disease: gene defects in 150 unrelated French cases with type 2 von Willebrand disease: from the patient to the gene. Thromb Haemost 1997; 78: 4516.
  • 31
    Budde U, Drewke E, Mainusch K, Schneppenheim R. Laboratory diagnosis of congenital von Willebrand disease. Semin Thromb Hemost 2002; 28: 17390.
  • 32
    Mannucci PM, Bloom AL, Larrieu MJ, Nilsson IM, West RR. Atherosclerosis and von Willebrand factor: I. Prevalence of severe von Willebrand’s disease in western Europe and Israel. Br J Haematol 1984; 57: 1639.
  • 33
    Weiss HJ, Ball AP, Mannucci PM. Incidence of severe von Willebrand’s disease. N Engl J Med 1982; 307: 127.
  • 34
    Berliner SA, Seligsohn U, Zivelin A, Zwang E, Sofferman G. A relatively high frequency of severe (type III) von Willebrand’s disease in Israel. Br J Haematol 1986; 62: 53543.
  • 35
    Goodeve A, Eikenboom J, Castaman G et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood 2007; 109: 11221 (Epub 19 September 2006).
  • 36
    James PD, Notley C, Hegadorn C et al. The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood 2007; 109: 14554 (Epub 10 August 2006).
  • 37
    Bodó I, Katsumi A, Tuley EA, Eikenboom JC, Dong Z, Sadler JE. Type 1 von Willebrand disease mutation Cys1149Arg causes intracellular retention and degradation of heterodimers: a possible general mechanism for dominant mutations of oligomeric proteins. Blood 2001; 98: 29739.
  • 38
    Casaña P, Martínez F, Haya S, Espinós C, Aznar JA. Association of the 3467C>T mutation (T1156M) in the von Willebrand’s factor gene with dominant type 1 von Willebrand’s disease. Ann Hematol 2001; 80: 3813.
  • 39
    Eikenboom JC, Matsushita T, Reitsma PH et al. Dominant type 1 von Willebrand disease caused by mutated cysteine residues in the D3 domain of von Willebrand factor. Blood 1996; 88: 243341.
  • 40
    Gavazova S, Gill JC, Scott JP et al. A mutation in the D4 domain of von Willebrand factor (VWF) results in a variant of type 1 von Willebrand disease with accelerated in vivo VWF clearance [abstract]. Blood 2002; 100(Suppl. ): 128a.
  • 41
    Lethagen S, Isaksson C, Schaedel C, Holmberg L. Von Willebrand’s disease caused by compound heterozygosity for a substitution mutation (T1156M) in the D3 domain of the von Willebrand factor and a stop mutation (Q2470X). Thromb Haemost 2002; 88: 4216.
  • 42
    Brown SA, Eldridge A, Collins PW, Bowen DJ. Increased clearance of von Willebrand factor antigen post-DDAVP in type 1 von Willebrand disease: is it a potential pathogenic process? J Thromb Haemost 2003; 1: 17147.
  • 43
    Casonato A, Pontara E, Sartorello F et al. Reduced von Willebrand factor survival in type Vicenza von Willebrand disease. Blood 2002; 99: 1804.
  • 44
    Schneppenheim R, Federici AB, Budde U et al. Von Willebrand disease type 2M ‘Vicenza’ in Italian and German patients: identification of the first candidate mutation (G3864A; R1205H) in 8 families. Thromb Haemost 2000; 83: 13640.
  • 45
    Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987; 69: 16915.
  • 46
    Mannucci PM, Lattuada A, Castaman G et al. Heterogeneous phenotypes of platelet and plasma von Willebrand factor in obligatory heterozygotes for severe von Willebrand disease. Blood 1989; 74: 24336.
  • 47
    Sadler JE. Von Willebrand disease type 1: a diagnosis in search of a disease. Blood 2003; 101: 208993 (Epub 31 October 2002).
  • 48
    Ruggeri ZM, Pareti FI, Mannucci PM, Ciavarella N, Zimmerman TS. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand’s disease. N Engl J Med 1980; 302: 104751.
  • 49
    Dent JA, Galbusera M, Ruggeri ZM. Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit. J Clin Invest 1991; 88: 77482.
  • 50
    Ginsburg D, Konkle BA, Gill JC et al. Molecular basis of human von Willebrand disease: analysis of platelet von Willebrand factor mRNA. Proc Natl Acad Sci U S A 1989; 86: 37237.
  • 51
    Lyons SE, Bruck ME, Bowie EJ, Ginsburg D. Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations. J Biol Chem 1992; 267: 442430.
  • 52
    Gaucher C, Diéval J, Mazurier C. Characterization of von Willebrand factor gene defects in two unrelated patients with type IIC von Willebrand disease. Blood 1994; 84: 102430.
  • 53
    Ruggeri ZM, Nilsson IM, Lombardi R, Holmberg L, Zimmerman TS. Aberrant multimeric structure of von Willebrand factor in a new variant of von Willebrand’s disease (type IIC). J Clin Invest 1982; 70: 11247.
  • 54
    Schneppenheim R, Thomas KB, Krey S et al. Identification of a candidate missense mutation in a family with von Willebrand disease type IIC. Hum Genet 1995; 95: 6816.
  • 55
    Kinoshita S, Harrison J, Lazerson J, Abildgaard CF. A new variant of dominant type II von Willebrand’s disease with aberrant multimeric pattern of factor VIII-related antigen (type IID). Blood 1984; 63: 136971.
  • 56
    Schneppenheim R, Brassard J, Krey S et al. Defective dimerization of von Willebrand factor subunits due to a Cys[RIGHTWARDS ARROW]Arg mutation in type IID von Willebrand disease. Proc Natl Acad Sci U S A 1996; 93: 35816.
  • 57
    Schneppenheim R, Budde U, Ruggeri ZM. A molecular approach to the classification of von Willebrand disease. Best Pract Res Clin Haematol 2001; 14: 28198.
  • 58
    Zimmerman TS, Dent JA, Ruggeri ZM, Nannini LH. Subunit composition of plasma von Willebrand factor: cleavage is present in normal individuals, increased in IIA and IIB von Willebrand disease, but minimal in variants with aberrant structure of individual oligomers (types IIC, IID, and IIE). J Clin Invest 1986; 77: 94751.
  • 59
    Sutherland JJ, O’Brien LA, Lillicrap D, Weaver DF. Molecular modeling of the von Willebrand factor A2 domain and the effects of associated type 2A von Willebrand disease mutations. J Mol Model 2004; 10: 25970 (Epub 3 August 2004).
  • 60
    Ruggeri ZM, Zimmerman TS. Variant von Willebrand’s disease: characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets. J Clin Invest 1980; 65: 131825.
  • 61
    Lankhof H, Damas C, Schiphorst ME et al. Functional studies on platelet adhesion with recombinant von Willebrand factor type 2B mutants R543Q and R543W under conditions of flow. Blood 1997; 89: 276672.
  • 62
    Giles AR, Hoogendoorn H, Benford K. Type IIB von Willebrand’s disease presenting as thrombocytopenia during pregnancy. Br J Haematol 1987; 67: 34953.
  • 63
    Hultin MB, Sussman II. Postoperative thrombocytopenia in type IIB von Willebrand disease. Am J Hematol 1990; 33: 648.
  • 64
    Rick ME, Williams SB, Sacher RA, McKeown LP. Thrombocytopenia associated with pregnancy in a patient with type IIB von Willebrand’s disease. Blood 1987; 69: 7869.
  • 65
    Casonato A, Fabris F, Girolami A. Platelet aggregation and pseudothrombocytopenia induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in type IIB von Willebrand’s disease patient. Eur J Haematol 1990; 45: 3642.
  • 66
    Casonato A, Sartori MT, De Marco L, Girolami A. 1-Desamino-8-D-arginine vasopressin (DDAVP) infusion in type IIB von Willebrand’s disease: shortening of bleeding time and induction of a variable pseudothrombocytopenia. Thromb Haemost 1990; 64: 11720.
  • 67
    Cooney KA, Nichols WC, Bruck ME et al. The molecular defect in type IIB von Willebrand disease: identification of four potential missense mutations within the putative GpIb binding domain. J Clin Invest 1991; 87: 122733.
  • 68
    Kroner PA, Kluessendorf ML, Scott JP, Montgomery RR. Expressed full-length von Willebrand factor containing missense mutations linked to type IIB von Willebrand disease shows enhanced binding to platelets. Blood 1992; 79: 204855.
  • 69
    Meyer D, Fressinaud E, Hilbert L, Ribba AS, Lavergne JM, Mazurier C. Type 2 von Willebrand disease causing defective von Willebrand factor-dependent platelet function. Best Pract Res Clin Haematol 2001; 14: 34964.
  • 70
    Randi AM, Rabinowitz I, Mancuso DJ, Mannucci PM, Sadler JE. Molecular basis of von Willebrand disease type IIB: candidate mutations cluster in one disulfide loop between proposed platelet glycoprotein Ib binding sequences. J Clin Invest 1991; 87: 12206.
  • 71
    Huizinga EG, Tsuji S, Romijn RA et al. Structures of glycoprotein Ibα and its complex with von Willebrand factor A1 domain. Science 2002; 297: 11769.
  • 72
    Hillery CA, Mancuso DJ, Sadler JE et al. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets. Blood 1998; 91: 157281.
  • 73
    Mancuso DJ, Kroner PA, Christopherson PA, Vokac EA, Gill JC, Montgomery RR. Type 2M:Milwaukee-1 von Willebrand disease: an in-frame deletion in the Cys509-Cys695 loop of the von Willebrand factor A1 domain causes deficient binding of von Willebrand factor to platelets. Blood 1996; 88: 255968.
  • 74
    Rabinowitz I, Tuley EA, Mancuso DJ et al. Von Willebrand disease type B: a missense mutation selectively abolishes ristocetin-induced von Willebrand factor binding to platelet glycoprotein Ib. Proc Natl Acad Sci U S A 1992; 89: 98469.
  • 75
    Ribba AS, Loisel I, Lavergne JM et al. Ser968Thr mutation within the A3 domain of von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen. Thromb Haemost 2001; 86: 84854.
  • 76
    Mazurier C, Dieval J, Jorieux S, Delobel J, Goudemand M. A new von Willebrand factor (vWF) defect in a patient with factor VIII (FVIII) deficiency but with normal levels and multimeric patterns of both plasma and platelet vWF: characterization of abnormal vWF/FVIII interaction. Blood 1990; 75: 206.
  • 77
    Montgomery RR, Hathaway WE, Johnson J, Jacobson L, Muntean W. A variant of von Willebrand’s disease with abnormal expression of factor VIII procoagulant activity. Blood 1982; 60: 2017.
  • 78
    Nishino M, Girma JP, Rothschild C, Fressinaud E, Meyer D. New variant of von Willebrand disease with defective binding to factor VIII. Blood 1989; 74: 15919.
  • 79
    Mazurier C, Meyer D, Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH. Factor VIII binding assay of von Willebrand factor and the diagnosis of type 2N von Willebrand disease: results of an international survey. Thromb Haemost 1996; 76: 2704.
  • 80
    Schneppenheim R, Budde U, Krey S et al. Results of a screening for von Willebrand disease type 2N in patients with suspected haemophilia A or von Willebrand disease type 1. Thromb Haemost 1996; 76: 598602.
  • 81
    Kroner PA, Friedman KD, Fahs SA, Scott JP, Montgomery RR. Abnormal binding of factor VIII is linked with the substitution of glutamine for arginine 91 in von Willebrand factor in a variant form of von Willebrand disease. J Biol Chem 1991; 266: 191469.
  • 82
    Mazurier C, Goudemand J, Hilbert L, Caron C, Fressinaud E, Meyer D. Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology. Best Pract Res Clin Haematol 2001; 14: 33747.
  • 83
    Allen S, Abuzenadah AM, Blagg JL et al. Two novel type 2N von Willebrand disease-causing mutations that result in defective factor VIII binding, multimerization, and secretion of von Willebrand factor. Blood 2000; 95: 20007.
  • 84
    Hilbert L, D’Oiron R, Fressinaud E, Meyer D, Mazurier C, INSERM Network on Molecular Abnormalities in von Willebrand Disease. First identification and expression of a type 2N von Willebrand disease mutation (E1078K) located in exon 25 of von Willebrand factor gene. J Thromb Haemost 2004; 2: 22713.
  • 85
    Hilbert L, Jorieux S, Proulle V et al. Two novel mutations, Q1053H and C1060R, located in the D3 domain of von Willebrand factor, are responsible for decreased FVIII-binding capacity. Br J Haematol 2003; 120: 62732.
  • 86
    Italian Working Group. Spectrum of von Willebrand’s disease: a study of 100 cases. Br J Haematol 1977; 35: 10112.
  • 87
    Lak M, Peyvandi F, Mannucci PM. Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. Br J Haematol 2000; 111: 12369.
  • 88
    Zhang ZP, Lindstedt M, Falk G, Blomback M, Egberg N, Anvret M. Nonsense mutations of the von Willebrand factor gene in patients with von Willebrand disease type III and type I. Am J Hum Genet 1992; 51: 8508.
  • 89
    Baronciani L, Cozzi G, Canciani MT et al. Molecular defects in type 3 von Willebrand disease: updated results from 40 multiethnic patients. Blood Cells Mol Dis 2003; 30: 26470.
  • 90
    Eikenboom JC. Congenital von Willebrand disease type 3: clinical manifestations, pathophysiology and molecular biology. Best Pract Res Clin Haematol 2001; 14: 36579.
  • 91
    Mannucci PM, Federici AB. Antibodies to von Willebrand factor in von Willebrand disease. Adv Exp Med Biol 1995; 386: 8792.
  • 92
    Mannucci PM, Ruggeri ZM, Ciavarella N, Kazatchkine MD, Mowbray JF. Precipitating antibodies to factor VIII/von Willebrand factor in von Willebrand’s disease: effects on replacement therapy. Blood 1981; 57: 2531.
  • 93
    Nitu-Whalley IC, Riddell A, Lee CA et al. Identification of type 2 von Willebrand disease in previously diagnosed type 1 patients: a reappraisal using phenotypes, genotypes and molecular modeling. Thromb Haemost 2000; 84: 9981004.
  • 94
    Mannucci PM, Lombardi R, Castaman G et al. Von Willebrand disease ‘Vicenza’ with larger-than-normal (supranormal) von Willebrand factor multimers. Blood 1988; 71: 6570.
  • 95
    Sadler JE. New concepts in von Willebrand disease. Annu Rev Med 2005; 56: 17391.
  • 96
    Castaman G, Rodeghiero F, Mannucci PM. The elusive pathogenesis of von Willebrand disease Vicenza. Blood 2002; 99: 42434.
  • 97
    Bodó I, Katsumi A, Tuley EA, Schlammadinger A, Boda Z, Sadler JE. Mutation causing dominant type 1 von Willebrand disease with high penetrance [abstract]. Blood 1999; 94(Suppl. ): 373a.
  • 98
    Castaman G, Eikenboom JC, Missiaglia E, Rodeghiero F. Autosomal dominant type 1 von Willebrand disease due to G3639T mutation (C1130F) in exon 26 of von Willebrand factor gene: description of five Italian families and evidence for a founder effect. Br J Haematol 2000; 108: 8769.
  • 99
    Eikenboom J, Van Marion V, Putter H et al. Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD. J Thromb Haemost 2006; 4: 77482.
  • 100
    James PD, Paterson AD, Notley C et al. Genetic linkage and association analysis in type 1 von Willebrand disease: results from the Canadian type 1 VWD study. J Thromb Haemost 2006; 4: 78392.
  • 101
    Mannucci PM, Lombardi R, Bader R et al. Heterogeneity of type I von Willebrand disease: evidence for a subgroup with an abnormal von Willebrand factor. Blood 1985; 66: 796802.
  • 102
    Casaña P, Martínez F, Haya S, Espinós C, Aznar JA. Significant linkage and non-linkage of type 1 von Willebrand disease to the von Willebrand factor gene. Br J Haematol 2001; 115: 692700.
  • 103
    Castaman G, Eikenboom JC, Bertina RM, Rodeghiero F. Inconsistency of association between type 1 von Willebrand disease phenotype and genotype in families identified in an epidemiological investigation. Thromb Haemost 1999; 82: 106570.
  • 104
    Miller CH, Graham JB, Goldin LR, Elston RC. Genetics of classic von Willebrand’s disease: I. Phenotypic variation within families. Blood 1979; 54: 11736.
  • 105
    Souto JC, Almasy L, Borrell M et al. Genetic determinants of hemostasis phenotypes in Spanish families. Circulation 2000; 101: 154651.
  • 106
    Vossen CY, Hasstedt SJ, Rosendaal FR et al. Heritability of plasma concentrations of clotting factors and measures of a prethrombotic state in a protein C-deficient family. J Thromb Haemost 2004; 2: 2427.
  • 107
    De Lange M, Snieder H, Ariens RA, Spector TD, Grant PJ. The genetics of haemostasis: a twin study. Lancet 2001; 357: 1015.
  • 108
    Ørstavik KH, Magnus P, Reisner H, Berg K, Graham JB, Nance W. Factor VIII and factor IX in a twin population: evidence for a major effect of ABO locus on factor VIII level. Am J Hum Genet 1985; 37: 89101.
  • 109
    Harrap SB, Hopper JL. Genetics of haemostasis. Lancet 2001; 357: 834.
  • 110
    De Visser MC, Sandkuijl LA, Lensen RP, Vos HL, Rosendaal FR, Bertina RM. Linkage analysis of factor VIII and von Willebrand factor loci as quantitative trait loci. J Thromb Haemost 2003; 1: 17716.
  • 111
    O’Donnell J, Boulton FE, Manning RA, Laffan MA. Genotype at the secretor blood group locus is a determinant of plasma von Willebrand factor level. Br J Haematol 2002; 116: 3506.
  • 112
    Souto JC, Almasy L, Soria JM et al. Genome-wide linkage analysis of von Willebrand factor plasma levels: results from the GAIT project. Thromb Haemost 2003; 89: 46874.
  • 113
    Schneppenheim R, Krey S, Bergmann F et al. Genetic heterogeneity of severe von Willebrand disease type III in the German population. Hum Genet 1994; 94: 64052.
  • 114
    Federici AB, Rand JH, Bucciarelli P et al. Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost 2000; 84: 3459 (Erratum in: Thromb Haemost 2000; 84: 739).
  • 115
    Veyradier A, Jenkins CS, Fressinaud E, Meyer D. Acquired von Willebrand syndrome: from pathophysiology to management. Thromb Haemost 2000; 84: 17582.
  • 116
    Gill JC, Wilson AD, Endres-Brooks J, Montgomery RR. Loss of the largest von Willebrand factor multimers from the plasma of patients with congenital cardiac defects. Blood 1986; 67: 75861.
  • 117
    Rauch R, Budde U, Koch A, Girisch M, Hofbeck M. Acquired von Willebrand syndrome in children with patent ductus arteriosus. Heart 2002; 88: 878.
  • 118
    Veyradier A, Nishikubo T, Humbert M et al. Improvement of von Willebrand factor proteolysis after prostacyclin infusion in severe pulmonary arterial hypertension. Circulation 2000; 102: 24602.
  • 119
    Vincentelli A, Susen S, Le Tourneau T et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 2003; 349: 3439.
  • 120
    Budde U, Scharf RE, Franke P, Hartmann-Budde K, Dent J, Ruggeri ZM. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood 1993; 82: 174957.
  • 121
    Mazzucconi MG, Ferrari A, Solinas S et al. Studies of von Willebrand factor in essential thrombocythemia patients treated with alpha-2b recombinant interferon. Haemostasis 1991; 21: 13540.
  • 122
    Van Genderen PJ, Budde U, Michiels JJ, Van Strik R, Van Vliet HH. The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count. Br J Haematol 1996; 93: 9625.
  • 123
    Tefferi A, Nichols WL. Acquired von Willebrand disease: concise review of occurrence, diagnosis, pathogenesis, and treatment. Am J Med 1997; 103: 53640.
  • 124
    Dalton RG, Dewar MS, Savidge GF et al. Hypothyroidism as a cause of acquired von Willebrand’s disease. Lancet 1987; 1: 10079.
  • 125
    Lo B, Fijnheer R, Castigliego D, Borst C, Kalkman CJ, Nierich AP. Activation of hemostasis after coronary artery bypass grafting with or without cardiopulmonary bypass. Anesth Analg 2004; 99: 63440.
  • 126
    Cortellaro M, Boschetti C, Cofrancesco E et al. The PLAT Study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients: principal results. Arterioscler Thromb 1992; 12: 106370.
  • 127
    Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1997; 96: 11028.
  • 128
    Thompson SG, Kienast J, Pyke SD, Haverkate F, Van De Loo JC, European Concerted Action on Thrombosis, Disabilities Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 63541.
  • 129
    Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 2003; 107: 31415 (Epub 9 June 2003).
  • 130
    Moake JL. Von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura. Semin Hematol 2004; 41: 414.
  • 131
    Tsai HM. Shear stress and von Willebrand factor in health and disease. Semin Thromb Hemost 2003; 29: 47988.
  • 132
    Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 1525.
  • 133
    Federici AB. Clinical diagnosis of von Willebrand disease. Haemophilia 2004; 10(Suppl. ): 16976.
  • 134
    Silwer J. Von Willebrand’s disease in Sweden. Acta Paediatr Scand Suppl 1973; 238: 1159.
  • 135
    Sramek A, Eikenboom JC, Briet E, Vandenbroucke JP, Rosendaal FR. Usefulness of patient interview in bleeding disorders. Arch Intern Med 1995; 155: 140915.
  • 136
    Mauser Bunschoten EP, Van Houwelingen JC, Sjamsoedin Visser EJ, Van Dijken PJ, Kok AJ, Sixma JJ. Bleeding symptoms in carriers of hemophilia A and B. Thromb Haemost 1988; 59: 34952.
  • 137
    Nosek-Cenkowska B, Cheang MS, Pizzi NJ, Israels ED, Gerrard JM. Bleeding/bruising symptomatology in children with and without bleeding disorders. Thromb Haemost 1991; 65: 23741.
  • 138
    Wahlberg T, Blomback M, Hall P, Axelsson G. Application of indicators, predictors and diagnostic indices in coagulation disorders: II. Evaluation of laboratory variables with continuous test results. Methods Inf Med 1980; 19: 2015.
  • 139
    Kirtava A, Drews C, Lally C, Dilley A, Evatt B. Medical, reproductive and psychosocial experiences of women diagnosed with von Willebrand’s disease receiving care in haemophilia treatment centres: a case-control study. Haemophilia 2003; 9: 2927.
  • 140
    Dilley A, Drews C, Miller C et al. Von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia. Obstet Gynecol 2001; 97: 6306.
  • 141
    Edlund M, Blomback M, Von Schoultz B, Andersson O. On the value of menorrhagia as a predictor for coagulation disorders. Am J Hematol 1996; 53: 2348.
  • 142
    Goodman-Gruen D, Hollenbach K. The prevalence of von Willebrand disease in women with abnormal uterine bleeding. J Womens Health Gend Based Med 2001; 10: 67780.
  • 143
    James AH, Lukes AS, Brancazio LR, Thames E, Ortel TL. Use of a new platelet function analyzer to detect von Willebrand disease in women with menorrhagia. Am J Obstet Gynecol 2004; 191: 44955.
  • 144
    Kadir RA, Economides DL, Sabin CA, Owens D, Lee CA. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet 1998; 351: 4859.
  • 145
    Philipp CS, Dilley A, Miller CH et al. Platelet functional defects in women with unexplained menorrhagia. J Thromb Haemost 2003; 1: 47784.
  • 146
    Woo YL, White B, Corbally R et al. Von Willebrand’s disease: an important cause of dysfunctional uterine bleeding. Blood Coagul Fibrinolysis 2002; 13: 8993.
  • 147
    Warner PE, Critchley HO, Lumsden MA, Campbell-Brown M, Douglas A, Murray GD. Menorrhagia: I. Measured blood loss, clinical features, and outcome in women with heavy periods: a survey with follow-up data. Am J Obstet Gynecol 2004; 190: 121623.
  • 148
    Drews CD, Dilley AB, Lally C, Beckman MG, Evatt B. Screening questions to identify women with von Willebrand disease. J Am Med Womens Assoc 2002; 57: 2178.
  • 149
    Rodeghiero F, Castaman G, Tosetto A et al. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. J Thromb Haemost 2005; 3: 261926 (Erratum in: J Thromb Haemost 2006; 4: 925).
  • 150
    Tosetto A, Rodeghiero F, Castaman G et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006; 4: 76673.
  • 151
    Castaman G, Rodeghiero F, Tosetto A et al. Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study. J Thromb Haemost 2006; 4: 21649.
  • 152
    Kumar S, Pruthi RK, Nichols WL. Acquired von Willebrand’s syndrome: a single institution experience. Am J Hematol 2003; 72: 2437.
  • 153
    Rodgers RP, Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost 1990; 16: 120.
  • 154
    Cattaneo M, Federici AB, Lecchi A et al. Evaluation of the PFA-100 system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease. Thromb Haemost 1999; 82: 359.
  • 155
    Cattaneo M, Lecchi A, Agati B, Lombardi R, Zighetti ML. Evaluation of platelet function with the PFA-100 system in patients with congenital defects of platelet secretion. Thromb Res 1999; 96: 2137.
  • 156
    Fressinaud E, Veyradier A, Truchaud F et al. Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases. Blood 1998; 91: 132531.
  • 157
    Quiroga T, Goycoolea M, Munoz B et al. Template bleeding time and PFA-100 have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: comparative study in 148 patients. J Thromb Haemost 2004; 2: 8928 (Erratum in: J Thromb Haemost 2005; 3: 622).
  • 158
    Dean JA, Blanchette VS, Carcao MD et al. Von Willebrand disease in a pediatric-based population: comparison of type 1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen-binding assay. Thromb Haemost 2000; 84: 4019.
  • 159
    Posan E, McBane RD, Grill DE, Motsko CL, Nichols WL. Comparison of PFA-100 testing and bleeding time for detecting platelet hypofunction and von Willebrand disease in clinical practice. Thromb Haemost 2003; 90: 48390.
  • 160
    Schlammadinger A, Kerenyi A, Muszbek L, Boda Z. Comparison of the O’Brien filter test and the PFA-100 platelet analyzer in the laboratory diagnosis of von Willebrand’s disease. Thromb Haemost 2000; 84: 8892.
  • 161
    Cariappa R, Wilhite TR, Parvin CA, Luchtman-Jones L. Comparison of PFA-100 and bleeding time testing in pediatric patients with suspected hemorrhagic problems. J Pediatr Hematol Oncol 2003; 25: 4749.
  • 162
    Kunicki TJ, Baronciani L, Canciani MT et al. An association of candidate gene haplotypes and bleeding severity in von Willebrand disease type 2A, 2B, and 2M pedigrees. J Thromb Haemost 2006; 4: 13747.
  • 163
    Michiels JJ, Van De Velde A, Van Vliet HH, Van Der Planken M, Schroyens W, Berneman Z. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications. Semin Thromb Hemost 2002; 28: 11132.
  • 164
    Federici AB, Canciani MT, Forza I et al. A sensitive ristocetin co-factor activity assay with recombinant glycoprotein Ibα for the diagnosis of patients with low von Willebrand factor levels. Haematologica 2004; 89: 7785.
  • 165
    Vanhoorelbeke K, Cauwenberghs N, Vauterin S, Schlammadinger A, Mazurier C, Deckmyn H. A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factor. Thromb Haemost 2000; 83: 10713.
  • 166
    Vanhoorelbeke K, Pareyn I, Schlammadinger A et al. Plasma glycocalicin as a source of GPIbα in the von Willebrand factor ristocetin cofactor ELISA. Thromb Haemost 2005; 93: 16571.
  • 167
    Murdock PJ, Woodhams BJ, Matthews KB, Pasi KJ, Goodall AH. Von Willebrand factor activity detected in a monoclonal antibody-based ELISA: an alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use. Thromb Haemost 1997; 78: 12727.
  • 168
    Caron C, Hilbert L, Vanhoorelbeke K, Deckmyn H, Goudemand J, Mazurier C. Measurement of von Willebrand factor binding to a recombinant fragment of glycoprotein Ibα in an enzyme-linked immunosorbent assay-based method: performances in patients with type 2B von Willebrand disease. Br J Haematol 2006; 133: 65563.
  • 169
    Fischer BE, Thomas KB, Dorner F. Von Willebrand factor: measuring its antigen or function? Correlation between the level of antigen, activity, and multimer size using various detection systems. Thromb Res 1998; 91: 3943.
  • 170
    Favaloro EJ, Bonar R, Kershaw G et al. Laboratory diagnosis of von Willebrand’s disorder: quality and diagnostic improvements driven by peer review in a multilaboratory test process. Haemophilia 2004; 10: 23242.
  • 171
    Favaloro EJ, Thom J, Baker R, Australasian Society for Thrombosis, Haemostasis (ASTH) Emerging Technologies Group. Assessment of current diagnostic practice and efficacy in testing for von Willebrand’s disorder: results from the second Australasian multi-laboratory survey. Blood Coagul Fibrinolysis 2000; 11: 72937.
  • 172
    Hayes TE, Brandt JT, Chandler WL et al. External peer review quality assurance testing in von Willebrand disease: the recent experience of the United States College of American Pathologists proficiency testing program. Semin Thromb Hemost 2006; 32: 499504.
  • 173
    Kitchen S, Jennings I, Woods TA, Kitchen DP, Walker ID, Preston FE. Laboratory tests for measurement of von Willebrand factor show poor agreement among different centers: results from the United Kingdom National External Quality Assessment Scheme for Blood Coagulation. Semin Thromb Hemost 2006; 32: 4928.
  • 174
    Meijer P, Haverkate F. An external quality assessment program for von Willebrand factor laboratory analysis: an overview from the European concerted action on thrombosis and disabilities foundation. Semin Thromb Hemost 2006; 32: 48591.
  • 175
    Budde U, Pieconka A, Will K, Schneppenheim R. Laboratory testing for von Willebrand disease: contribution of multimer analysis to diagnosis and classification. Semin Thromb Hemost 2006; 32: 51421.
  • 176
    Studt JD, Budde U, Schneppenheim R et al. Quantification and facilitated comparison of von Willebrand factor multimer patterns by densitometry. Am J Clin Pathol 2001; 116: 56774.
  • 177
    Scott JP, Montgomery RR. The rapid differentiation of type IIb von Willebrand’s disease from platelet-type (pseudo-) von Willebrand’s disease by the ‘neutral’ monoclonal antibody binding assay. Am J Clin Pathol 1991; 96: 7238.
  • 178
    Favaloro EJ. Detection of von Willebrand disorder and identification of qualitative von Willebrand factor defects: direct comparison of commercial ELISA-based von Willebrand factor activity options. Am J Clin Pathol 2000; 114: 60818.
  • 179
    Neugebauer BM, Goy C, Budek I, Seitz R. Comparison of two von Willebrand factor collagen-binding assays with different binding affinities for low, medium, and high multimers of von Willebrand factor. Semin Thromb Hemost 2002; 28: 13948.
  • 180
    Favaloro EJ. Collagen binding assay for von Willebrand factor (VWF:CBA): detection of von Willebrand’s disease (VWD), and discrimination of VWD subtypes, depends on collagen source. Thromb Haemost 2000; 83: 12735.
  • 181
    Favaloro EJ, Henniker A, Facey D, Hertzberg M. Discrimination of von Willebrand’s disease (VWD) subtypes: direct comparison of von Willebrand factor:collagen binding assay (VWF:CBA) with monoclonal antibody (MAB) based VWF-capture systems. Thromb Haemost 2000; 84: 5417.
  • 182
    Kroner PA, Foster PA, Fahs SA, Montgomery RR. The defective interaction between von Willebrand factor and factor VIII in a patient with type 1 von Willebrand disease is caused by substitution of Arg19 and His54 in mature von Willebrand factor. Blood 1996; 87: 101321.
  • 183
    Rodgers SE, Lerda NV, Favaloro EJ et al. Identification of von Willebrand disease type 2N (Normandy) in Australia: a cross-laboratory investigation using different methods. Am J Clin Pathol 2002; 118: 26976.
  • 184
    Favaloro EJ, Lillicrap D, Lazzari MA et al. Von Willebrand disease: laboratory aspects of diagnosis and treatment. Haemophilia 2004; 10(Suppl. ): 1648.
  • 185
    Federici AB, Canciani MT, Forza I, Cozzi G. Ristocetin cofactor and collagen binding activities normalized to antigen levels for a rapid diagnosis of type 2 von Willebrand disease: single center comparison of four different assays. Thromb Haemost 2000; 84: 11278.
  • 186
    Veyradier A, Fressinaud E, Meyer D. Laboratory diagnosis of von Willebrand disease. Int J Clin Lab Res 1998; 28: 20110.
  • 187
    Tomasulo PA, Richards W, Bailey M, Gajewski M, Aster RH, Lazerson J. Preselection of donors to improve the quality of cryoprecipitate. Am J Hematol 1980; 8: 1916.
  • 188
    National Committee for Clinical Laboratory Standards (NCCLS). Assays of von Willebrand Factor Antigen and Ristocetin Cofactor Activity: Approved Guideline. Wayne, PA: NCCLS, 2002 (Publication H51-A).
  • 189
    Sadler JE, Rodeghiero F, ISTH SSC Subcommittee on von Willebrand Factor. Provisional criteria for the diagnosis of VWD type 1. J Thromb Haemost 2005; 3: 7757.
  • 190
    Favaloro EJ, Soltani S, McDonald J, Grezchnik E, Easton L, Favaloro JW. Reassessment of ABO blood group, sex, and age on laboratory parameters used to diagnose von Willebrand disorder: potential influence on the diagnosis vs the potential association with risk of thrombosis. Am J Clin Pathol 2005; 124: 9107 (Erratum in: Am J Clin Pathol 2006; 125: 796).
  • 191
    Nitu-Whalley IC, Lee CA, Griffioen A, Jenkins PV, Pasi KJ. Type 1 von Willebrand disease: a clinical retrospective study of the diagnosis, the influence of the ABO blood group and the role of the bleeding history. Br J Haematol 2000; 108: 25964.
  • 192
    Ginsburg D. Molecular genetics of von Willebrand disease. Thromb Haemost 1999; 82: 58591.
  • 193
    Montgomery RR, Kroner PA. Von Willebrand disease: a common pediatric disorder. Pediatr Ann 2001; 30: 53440.
  • 194
    Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998; 67: 395424.
  • 195
    Montgomery RR. Structure and function of von Willebrand factor. In: ColmanRW, HirshJ, MarderVJ, ClowesAW, GeorgeJN, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 4th edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2001: 24974.
  • 196
    Montgomery RR, Coller BS. von Willebrand disease. In: ColmanRW, HirshJ, MarderVJ, SalzmanEW, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 3rd edn. Philadelphia, PA: JB Lippincott Company, 1993: 13468.
  • 197
    Van Genderen PJ, Boertjes RC, Van Mourik JA. Quantitative analysis of von Willebrand factor and its propeptide in plasma in acquired von Willebrand syndrome. Thromb Haemost 1998; 80: 4958.
  • 198
    Shelton-Inloes BB, Chehab FF, Mannucci PM, Federici AB, Sadler JE. Gene deletions correlate with the development of alloantibodies in von Willebrand disease. J Clin Invest 1987; 79: 145965.
  • 199
    Eikenboom JC, Reitsma PH, Peerlinck KM, Briet E. Recessive inheritance of von Willebrand’s disease type I. Lancet 1993; 341: 9826.
  • 200
    Sadler JE. Slippery criteria for von Willebrand disease type 1. J Thromb Haemost 2004; 2: 17203.
  • 201
    National Committee for Clinical Laboratory Standards (NCCLS). Collection, Transport, and Processing of Blood Specimens for Testing Plasma-based Coagulation Assays: Approved Guideline. Wayne, PA: NCCLS, 2003 (Publication H21-A4).
  • 202
    Favaloro EJ, Nair SC, Forsyth CJ. Collection and transport of samples for laboratory testing in von Willebrand’s disease (VWD): time for a reappraisal? Thromb Haemost 2001; 86: 158990.
  • 203
    Favaloro EJ, Soltani S, McDonald J. Potential laboratory misdiagnosis of hemophilia and von Willebrand disorder owing to cold activation of blood samples for testing. Am J Clin Pathol 2004; 122: 68692.
  • 204
    Preston FE, Kitchen S. Quality control and factor VIII assays. Haemophilia 1998; 4: 6513.
  • 205
    Preston FE, Kitchen S, Jennings I, Woods TA, Makris M. SSC/ISTH classification of hemophilia A: can hemophilia center laboratories achieve the new criteria? J Thromb Haemost 2004; 2: 2714.
  • 206
    Van Den Besselaar AM, Haas FJ, Kuypers AW. Harmonisation of factor VIII:C assay results: study within the framework of the Dutch project ‘Calibration 2000’. Br J Haematol 2006; 132: 759.
  • 207
    Centers for Disease Control and Prevention. Bleeding and Clotting Disorders Surveillance [Homepage on the Internet]. Atlanta, GA: Centers for Disease Control and Prevention. Available at: http://www2a.cdc.gov/ncbddd/htcweb/ (last accessed 23.01.2008).
  • 208
    Berntorp E, Petrini P. Long-term prophylaxis in von Willebrand disease. Blood Coagul Fibrinolysis 2005; 16(Suppl.): S236.
  • 209
    Sumner M, Williams J. Type 3 von Willebrand disease: assessment of complications and approaches to treatment: results of a patient and Hemophilia Treatment Center Survey in the United States. Haemophilia 2004; 10: 3606.
  • 210
    Kaufmann JE, Vischer UM. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Haemost 2003; 1: 6829.
  • 211
    Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 1997; 90: 251521.
  • 212
    Mannucci PM. Treatment of von Willebrand’s disease. N Engl J Med 2004; 351: 68394.
  • 213
    Kobrinsky NL, Doyle JJ, Israels ED et al. Absent factor VIII response to synthetic vasopressin analogue (DDAVP) in nephrogenic diabetes insipidus. Lancet 1985; 1: 12934.
  • 214
    Kaufmann JE, Oksche A, Wollheim CB, Gunther G, Rosenthal W, Vischer UM. Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. J Clin Invest 2000; 106: 10716.
  • 215
    Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. 1-Desamino-8-D-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands’ diseases. Lancet 1977; 1: 86972.
  • 216
    Cash JD, Gader AM, Da Costa J. Proceedings: the release of plasminogen activator and factor VIII to lysine vasopressin, arginine vasopressin, I-desamino-8-D-arginine vasopressin, angiotensin and oxytocin in man. Br J Haematol 1974; 27: 3634.
  • 217
    Mannucci PM, Aberg M, Nilsson IM, Robertson B. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol 1975; 30: 8193.
  • 218
    Mannucci PM, Canciani MT, Rota L, Donovan BS. Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand’s disease. Br J Haematol 1981; 47: 28393.
  • 219
    Lethagen S, Harris AS, Sjorin E, Nilsson IM. Intranasal and intravenous administration of desmopressin: effect on F VIII/vWF, pharmacokinetics and reproducibility. Thromb Haemost 1987; 58: 10336.
  • 220
    De La Fuente B, Kasper CK, Rickles FR, Hoyer LW. Response of patients with mild and moderate hemophilia A and von Willebrand’s disease to treatment with desmopressin. Ann Intern Med 1985; 103: 614.
  • 221
    Rodeghiero F, Castaman G, Di Bona E, Ruggeri M. Consistency of responses to repeated DDAVP infusions in patients with von Willebrand’s disease and hemophilia A. Blood 1989; 74: 199200.
  • 222
    Mannucci PM, Bettega D, Cattaneo M. Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). Br J Haematol 1992; 82: 8793.
  • 223
    Revel-Vilk S, Schmugge M, Carcao MD, Blanchette P, Rand ML, Blanchette VS. Desmopressin (DDAVP) responsiveness in children with von Willebrand disease. J Pediatr Hematol Oncol 2003; 25: 8749.
  • 224
    Federici AB, Mazurier C, Berntorp E et al. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood 2004; 103: 20328 (Epub 20 November 2003).
  • 225
    Rodeghiero F, Castaman G, Di Bona E, Ruggeri M, Lombardi R, Mannucci PM. Hyper-responsiveness to DDAVP for patients with type I von Willebrand’s disease and normal intra-platelet von Willebrand factor. Eur J Haematol 1988; 40: 1637.
  • 226
    McKeown LP, Connaghan G, Wilson O, Hansmann K, Merryman P, Gralnick HR. 1-Desamino-8-arginine-vasopressin corrects the hemostatic defects in type 2B von Willebrand’s disease. Am J Hematol 1996; 51: 15863.
  • 227
    Castaman G, Rodeghiero F. Desmopressin and type II B von Willebrand disease. Haemophilia 1996; 2: 737.
  • 228
    Mazurier C, Gaucher C, Jorieux S, Goudemand M, Collaborative Group. Biological effect of desmopressin in eight patients with type 2N (‘Normandy’) von Willebrand disease. Br J Haematol 1994; 88: 84954.
  • 229
    Castaman G, Lattuada A, Mannucci PM, Rodeghiero F. Factor VIII:C increases after desmopressin in a subgroup of patients with autosomal recessive severe von Willebrand disease. Br J Haematol 1995; 89: 14751.
  • 230
    Mannucci PM, Vicente V, Alberca I et al. Intravenous and subcutaneous administration of desmopressin (DDAVP) to hemophiliacs: pharmacokinetics and factor VIII responses. Thromb Haemost 1987; 58: 10379.
  • 231
    Bond L, Bevan D. Myocardial infarction in a patient with hemophilia treated with DDAVP. N Engl J Med 1988; 318: 121.
  • 232
    Byrnes JJ, Larcada A, Moake JL. Thrombosis following desmopressin for uremic bleeding. Am J Hematol 1988; 28: 635.
  • 233
    Virtanen R, Kauppila M, Itala M. Percutaneous coronary intervention with stenting in a patient with haemophilia A and an acute myocardial infarction following a single dose of desmopressin. Thromb Haemost 2004; 92: 11546.
  • 234
    Ruggeri ZM, Mannucci PM, Lombardi R, Federici AB, Zimmerman TS. Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand’s disease subtypes. Blood 1982; 59: 12728.
  • 235
    Schooten CJ, Tjernberg P, Westein E et al. Cysteine-mutations in von Willebrand factor associated with increased clearance. J Thromb Haemost 2005; 3: 222837.
  • 236
    Casonato A, Steffan A, Pontara E et al. Post-DDAVP thrombocytopenia in type 2B von Willebrand disease is not associated with platelet consumption: failure to demonstrate glycocalicin increase or platelet activation. Thromb Haemost 1999; 81: 2248.
  • 237
    Federici AB, Sacco R, Stabile F, Carpenedo M, Zingaro E, Mannucci PM. Optimising local therapy during oral surgery in patients with von Willebrand disease: effective results from a retrospective analysis of 63 cases. Haemophilia 2000; 6: 717.
  • 238
    Mariana G, Ciavarella N, Mazzucconi MG et al. Evaluation of the effectiveness of DDAVP in surgery and in bleeding episodes in haemophilia and von Willebrand’s disease: a study on 43 patients. Clin Lab Haematol 1984; 6: 22938.
  • 239
    Nitu-Whalley IC, Griffioen A, Harrington C, Lee CA. Retrospective review of the management of elective surgery with desmopressin and clotting factor concentrates in patients with von Willebrand disease. Am J Hematol 2001; 66: 2804.
  • 240
    Saulnier J, Marey A, Horellou MH et al. Evaluation of desmopressin for dental extractions in patients with hemostatic disorders. Oral Surg Oral Med Oral Pathol 1994; 77: 612.
  • 241
    Theiss W, Schmidt G. DDAVP in von Willebrand’s disease: repeated administration and the behaviour of the bleeding time. Thromb Res 1978; 13: 111923.
  • 242
    Shah SB, Lalwani AK, Koerper MA. Perioperative management of von Willebrand’s disease in otolaryngologic surgery. Laryngoscope 1998; 108: 326.
  • 243
    Allen GC, Armfield DR, Bontempo FA, Kingsley LA, Goldstein NA, Post JC. Adenotonsillectomy in children with von Willebrand disease. Arch Otolaryngol Head Neck Surg 1999; 125: 54751.
  • 244
    Derkay CS, Werner E, Plotnick E. Management of children with von Willebrand disease undergoing adenotonsillectomy. Am J Otolaryngol 1996; 17: 1727.
  • 245
    Jimenez-Yuste V, Prim MP, De Diego JI et al. Otolaryngologic surgery in children with von Willebrand disease. Arch Otolaryngol Head Neck Surg 2002; 128: 13658.
  • 246
    Kreuz W, Mentzer D, Becker S, Scharrer I, Kornhuber B. Haemate P in children with von Willebrand’s disease. Haemostasis 1994; 24: 30410.
  • 247
    Manno CS, Butler RB, Farace L, Cohen AR. Successful management of patients with type 1 von Willebrand’s disease with desmopressin acetate for tonsillectomy [abstract]. Haemophilia 1998; 4: 288.
  • 248
    Dobrkovska A, Krzensk U, Chediak JR. Pharmacokinetics, efficacy and safety of Humate-P in von Willebrand disease. Haemophilia 1998; 4(Suppl. ): 339.
  • 249
    Hanna WT, Bona RD, Zimmerman CE, Carta CA, Hebert GZ, Rickles FR. The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease. Thromb Haemost 1994; 71: 1739.
  • 250
    Lillicrap D, Poon MC, Walker I, Xie F, Schwartz BA, Association of Hemophilia Clinic Directors of Canada. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, Haemate-P/Humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost 2002; 87: 22430.
  • 251
    Lubetsky A, Schulman S, Varon D et al. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease. Thromb Haemost 1999; 81: 22933.
  • 252
    Michiels JJ, Berneman ZN, Van Der Planken M, Schroyens W, Budde U, Van Vliet HH. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P). Blood Coagul Fibrinolysis 2004; 15: 32330.
  • 253
    Thompson AR, Gill JC, Ewenstein BM, Mueller-Velten G, Schwartz BA, Humate-P Study Group. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P). Haemophilia 2004; 10: 4251.
  • 254
    Holmberg L, Nilsson IM, Borge L, Gunnarsson M, Sjorin E. Platelet aggregation induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in type IIB von Willebrand’s disease. N Engl J Med 1983; 309: 81621.
  • 255
    Fowler WE, Berkowitz LR, Roberts HR. DDAVP for type IIB von Willebrand disease. Blood 1989; 74: 185960.
  • 256
    Dunn AL, Powers JR, Ribeiro MJ, Rickles FR, Abshire TC. Adverse events during use of intranasal desmopressin acetate for haemophilia A and von Willebrand disease: a case report and review of 40 patients. Haemophilia 2000; 6: 114.
  • 257
    Lethagen S, Frick K, Sterner G. Antidiuretic effect of desmopressin given in hemostatic dosages to healthy volunteers. Am J Hematol 1998; 57: 1539.
  • 258
    Bertholini DM, Butler CS. Severe hyponatraemia secondary to desmopressin therapy in von Willebrand’s disease. Anaesth Intensive Care 2000; 28: 199201.
  • 259
    Das P, Carcao M, Hitzler J. DDAVP-induced hyponatremia in young children. J Pediatr Hematol Oncol 2005; 27: 3302.
  • 260
    Smith TJ, Gill JC, Ambruso DR, Hathaway WE. Hyponatremia and seizures in young children given DDAVP. Am J Hematol 1989; 31: 199202.
  • 261
    Sutor AH. DDAVP is not a panacea for children with bleeding disorders. Br J Haematol 2000; 108: 21727.
  • 262
    McLeod BC. Myocardial infarction in a blood donor after administration of desmopressin. Lancet 1990; 336: 11378.
  • 263
    Lowe GD. Desmopressin and myocardial infarction. Lancet 1989; 1: 8956.
  • 264
    Grunwald Z, Sather SD. Intraoperative cerebral infarction after desmopressin administration in infant with end-stage renal disease. Lancet 1995; 345: 13645.
  • 265
    Levi M, Cromheecke ME, De Jonge E et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 1999; 354: 19407.
  • 266
    Kouides PA. Females with von Willebrand disease: 72 years as the silent majority. Haemophilia 1998; 4: 66576.
  • 267
    Kujovich JL. Von Willebrand disease and pregnancy. J Thromb Haemost 2005; 3: 24653.
  • 268
    Mannucci PM. Use of desmopressin (DDAVP) during early pregnancy in factor VIII-deficient women. Blood 2005; 105: 3382.
  • 269
    Ray JG. DDAVP use during pregnancy: an analysis of its safety for mother and child. Obstet Gynecol Surv 1998; 53: 4505.
  • 270
    Agrawal YP, Dzik W. The vWF content of factor VIII concentrates. Transfusion 2001; 41: 1534.
  • 271
    Chang AC, Rick ME, Ross Pierce L, Weinstein MJ. Summary of a workshop on potency and dosage of von Willebrand factor concentrates. Haemophilia 1998; 4(Suppl. 5): 16.
  • 272
    Mannucci PM, Lattuada A, Ruggeri ZM. Proteolysis of von Willebrand factor in therapeutic plasma concentrates. Blood 1994; 83: 301827.
  • 273
    Morfini M, Mannucci PM, Tenconi PM et al. Pharmacokinetics of monoclonally-purified and recombinant factor VIII in patients with severe von Willebrand disease. Thromb Haemost 1993; 70: 2702.
  • 274
    Metzner HJ, Hermentin P, Cuesta-Linker T, Langner S, Muller HG, Friedebold J. Characterization of factor VIII/von Willebrand factor concentrates using a modified method of von Willebrand factor multimer analysis. Haemophilia 1998; 4(Suppl. ): 2532.
  • 275
    Humate-P [package insert]. King of Prussia, PA: CSL Behring, 2007.
  • 276
    Alphanate SD/HT [package insert]. Los Angeles, CA: Grifols, 2007.
  • 277
    Makris M, Colvin B, Gupta V, Shields ML, Smith MP. Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand’s disease. Thromb Haemost 2002; 88: 3878.
  • 278
    Mannucci PM. Venous thromboembolism in von Willebrand disease. Thromb Haemost 2002; 88: 3789.
  • 279
    Mannucci PM, Chediak J, Hanna W et al. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood 2002; 99: 4506.
  • 280
    Srivastava A. Von Willebrand disease in the developing world. Semin Hematol 2005; 42: 3641.
  • 281
    Budde U, Metzner HJ, Muller HG. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease. Semin Thromb Hemost 2006; 32: 62635.
  • 282
    Lethagen S, Carlson M, Hillarp A. A comparative in vitro evaluation of six von Willebrand factor concentrates. Haemophilia 2004; 10: 2439.
  • 283
    Turecek PL, Gritsch H, Richter G, Auer W, Pichler L, Schwarz HP. Assessment of bleeding for the evaluation of therapeutic preparations in small animal models of antibody-induced hemophilia and von Willebrand disease. Thromb Haemost 1997; 77: 5919.
  • 284
    US Food and Drug Administration. Additional Standards for Human Blood and Blood Products. [21 C.F.R. Sect. 640.54 (1 April 2006)].
  • 285
    Pomper GJ, Wu Y, Snyder EL. Risks of transfusion-transmitted infections: 2003. Curr Opin Hematol 2003; 10: 4128.
  • 286
    National Hemophilia Foundation. MASAC Document 177. MASAC Recommendations Concerning the Treatment of Hemophilia and other Bleeding Disorders (Revised October 2006) [Monograph on the Internet]. New York: National Hemophilia Foundation, c2006. Available at: http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contented=203
  • 287
    Evatt BL, Austin H, Leon G, Ruiz-Saez A, De Bosch N. Haemophilia therapy: assessing the cumulative risk of HIV exposure by cryoprecipitate. Haemophilia 1999; 5: 295300 (Erratum in: Haemophilia 2000; 6: 595).
  • 288
    Scharrer I, Vigh T, Aygoren-Pursun E. Experience with Haemate P in von Willebrand’s disease in adults. Haemostasis 1994; 24: 298303.
  • 289
    Castillo R, Escolar G, Monteagudo J, Aznar-Salatti J, Reverter JC, Ordinas A. Hemostasis in patients with severe von Willebrand disease improves after normal platelet transfusion and normalizes with further correction of the plasma defect. Transfusion 1997; 37: 78590.
  • 290
    Castillo R, Monteagudo J, Escolar G, Ordinas A, Magallon M, Martin Villar J. Hemostatic effect of normal platelet transfusion in severe von Willebrand disease patients. Blood 1991; 77: 19015.
  • 291
    Miller RA, May MW, Hendry WF, Whitfield HN, Wickham JE. The prevention of secondary haemorrhage after prostatectomy: the value of antifibrinolytic therapy. Br J Urol 1980; 52: 268.
  • 292
    Mannucci PM. Hemostatic drugs. N Engl J Med 1998; 339: 24553.
  • 293
    Rakocz M, Mazar A, Varon D, Spierer S, Blinder D, Martinowitz U. Dental extractions in patients with bleeding disorders: the use of fibrin glue. Oral Surg Oral Med Oral Pathol 1993; 75: 2802.
  • 294
    Zwischenberger JB, Brunston RL Jr, Swann JR, Conti VR. Comparison of two topical collagen-based hemostatic sponges during cardiothoracic procedures. J Invest Surg 1999; 12: 1016.
  • 295
    National Hemophilia Foundation. MASAC Recommendation #128: MASAC Recommendations for Hepatitis A and B Immunization of Individuals with Bleeding Disorders [Monograph on the Internet]. New York: National Hemophilia Foundation, c2006. Available at: http://www.hemophilia.org/research/masac/masac128.htm, accessed on November 2001.
  • 296
    Barbui T, Rodeghiero F, Dini E. The aspirin tolerance test in von Willebrand’s disease. Thromb Haemost 1977; 38: 5103.
  • 297
    Rosenstein R, Zacharski LR. The diagnostic value of the aspirin tolerance test. Thromb Res 1979; 16: 21930.
  • 298
    Stuart MJ, Miller ML, Davey FR, Wolk JA. The post-aspirin bleeding time: a screening test for evaluating haemostatic disorders. Br J Haematol 1979; 43: 64959.
  • 299
    Federici AB, Stabile F, Castaman G, Canciani MT, Mannucci PM. Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. Blood 1998; 92: 270711.
  • 300
    Arkel YS, Lynch J, Kamiyama M. Treatment of acquired von Willebrand syndrome with intravenous immunoglobulin. Thromb Haemost 1994; 72: 6434.
  • 301
    Macik BG, Gabriel DA, White GC II, High K, Roberts H. The use of high-dose intravenous gamma-globulin in acquired von Willebrand syndrome. Arch Pathol Lab Med 1988; 112: 1436.
  • 302
    Van Genderen PJ, Terpstra W, Michiels JJ, Kapteijn L, Van Vliet HH. High-dose intravenous immunoglobulin delays clearance of von Willebrand factor in acquired von Willebrand disease. Thromb Haemost 1995; 73: 8912.
  • 303
    Basso IN, Keeling D. Myocardial infarction following recombinant activated factor VII in a patient with type 2A von Willebrand disease. Blood Coagul Fibrinolysis 2004; 15: 5034.
  • 304
    Weinstein M, Ware JA, Troll J, Salzman E. Changes in von Willebrand factor during cardiac surgery: effect of desmopressin acetate. Blood 1988; 71: 164855.
  • 305
    Rahmani R, Rozen P, Papo J, Iellin A, Seligsohn U. Association of von Willebrand’s disease with plasma cell dyscrasia and gastrointestinal angiodysplasia. Isr J Med Sci 1990; 26: 5049.
  • 306
    Veyradier A, Balian A, Wolf M et al. Abnormal von Willebrand factor in bleeding angiodysplasias of the digestive tract. Gastroenterology 2001; 120: 34653.
  • 307
    Morris ES, Hampton KK, Nesbitt IM, Preston FE, Thomas EG, Makris M. The management of von Willebrand’s disease-associated gastrointestinal angiodysplasia. Blood Coagul Fibrinolysis 2001; 12: 1438.
  • 308
    Baumgartner-Parzer SM, Wagner L, Reining G et al. Increase by tri-iodothyronine of endothelin-1, fibronectin and von Willebrand factor in cultured endothelial cells. J Endocrinol 1997; 154: 2319.
  • 309
    Michiels JJ, Schroyens W, Berneman Z, Van Der Planken M. Acquired von Willebrand syndrome type 1 in hypothyroidism: reversal after treatment with thyroxine. Clin Appl Thromb Hemost 2001; 7: 1135.
  • 310
    Kirtava A, Crudder S, Dilley A, Lally C, Evatt B. Trends in clinical management of women with von Willebrand disease: a survey of 75 women enrolled in haemophilia treatment centres in the United States. Haemophilia 2004; 10: 15861.
  • 311
    Ragni MV, Bontempo FA, Hassett AC. Von Willebrand disease and bleeding in women. Haemophilia 1999; 5: 3137.
  • 312
    Chuong CJ, Brenner PF. Management of abnormal uterine bleeding. Am J Obstet Gynecol 1996; 175: 78792.
  • 313
    Kadir RA, Lee CA, Sabin CA, Pollard D, Economides DL. DDAVP nasal spray for treatment of menorrhagia in women with inherited bleeding disorders: a randomized placebo-controlled crossover study. Haemophilia 2002; 8: 78793.
  • 314
    James A, Matchar DB, Myers ER. Testing for von Willebrand disease in women with menorrhagia: a systematic review. Obstet Gynecol 2004; 104: 3818.
  • 315
    Schafer AI. Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis. J Clin Pharmacol 1995; 35: 20919.
  • 316
    Amesse LS, Pfaff-Amesse T, Leonardi R, Uddin D, French JA II. Oral contraceptives and DDAVP nasal spray: patterns of use in managing vWD-associated menorrhagia: a single-institution study. J Pediatr Hematol Oncol 2005; 27: 35763.
  • 317
    Petitti DB. Clinical practice: combination estrogen-progestin oral contraceptives. N Engl J Med 2003; 349: 144350 (Erratum in: N Engl J Med 2004; 350: 92).
  • 318
    Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Female hormones and thrombosis. Arterioscler Thromb Vasc Biol 2002; 22: 20110.
  • 319
    Beller FK, Ebert C. Effects of oral contraceptives on blood coagulation: a review. Obstet Gynecol Surv 1985; 40: 42536.
  • 320
    Kadir RA, Economides DL, Sabin CA, Owens D, Lee CA. Variations in coagulation factors in women: effects of age, ethnicity, menstrual cycle and combined oral contraceptive. Thromb Haemost 1999; 82: 145661.
  • 321
    Middeldorp S, Meijers JC, Van Den Ende AE et al. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost 2000; 84: 48.
  • 322
    Nilsson L, Rybo G. Treatment of menorrhagia. Am J Obstet Gynecol 1971; 110: 71320.
  • 323
    Milman N, Clausen J, Byg KE. Iron status in 268 Danish women aged 18-30 years: influence of menstruation, contraceptive method, and iron supplementation. Ann Hematol 1998; 77: 139.
  • 324
    Rivera R, Almonte H, Arreola M et al. The effects of three different regimens of oral contraceptives and three different intrauterine devices on the levels of hemoglobin, serum iron and iron binding capacity in anemic women. Contraception 1983; 27: 31127.
  • 325
    Task Force for Epidemiological Research on Reproductive Health, United Nations Development Programme/United Nations Population Fund/World Health Organization/World Bank Special Programme of Research, Development, Research Training in Human Reproduction, World Health Organization, Geneva, Switzerland. Effects of contraceptives on hemoglobin and ferritin. Contraception 1998; 58: 26273.
  • 326
    Grimes DA. The safety of oral contraceptives: epidemiologic insights from the first 30 years. Am J Obstet Gynecol 1992; 166: 19504.
  • 327
    Sicat BL. Ortho Evra, a new contraceptive patch. Pharmacotherapy 2003; 23: 47280.
  • 328
    Davis A, Godwin A, Lippman J, Olson W, Kafrissen M. Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding. Obstet Gynecol 2000; 96: 91320.
  • 329
    Greer IA, Lowe GD, Walker JJ, Forbes CD. Haemorrhagic problems in obstetrics and gynaecology in patients with congenital coagulopathies. Br J Obstet Gynaecol 1991; 98: 90918.
  • 330
    Kadir RA, Economides DL, Sabin CA, Pollard D, Lee CA. Assessment of menstrual blood loss and gynaecological problems in patients with inherited bleeding disorders. Haemophilia 1999; 5: 408.
  • 331
    Rubin G, Wortman M, Kouides PA. Endometrial ablation for von Willebrand disease-related menorrhagia: experience with seven cases. Haemophilia 2004; 10: 47782.
  • 332
    Bain C, Cooper KG, Parkin DE. Microwave endometrial ablation versus endometrial resection: a randomized controlled trial. Obstet Gynecol 2002; 99: 9837.
  • 333
    Boujida VH, Philipsen T, Pelle J, Joergensen JC. Five-year follow-up of endometrial ablation: endometrial coagulation versus endometrial resection. Obstet Gynecol 2002; 99: 98892.
  • 334
    Comino R, Torrejon R. Hysterectomy after endometrial ablation-resection. J Am Assoc Gynecol Laparosc 2004; 11: 4959.
  • 335
    Dutton C, Ackerson L, Phelps-Sandall B. Outcomes after rollerball endometrial ablation for menorrhagia. Obstet Gynecol 2001; 98: 359.
  • 336
    Phillips G, Chien PF, Garry R. Risk of hysterectomy after 1000 consecutive endometrial laser ablations. Br J Obstet Gynaecol 1998; 105: 897903.
  • 337
    Kuppermann M, Varner RE, Summitt RL Jr et al. Effect of hysterectomy vs medical treatment on health-related quality of life and sexual functioning: the medicine or surgery (Ms) randomized trial. JAMA 2004; 291: 144755.
  • 338
    Unger JB, Meeks GR. Hysterectomy after endometrial ablation. Am J Obstet Gynecol 1996; 175: 14326.
  • 339
    Foster PA, Subcommittee on von Willebrand Factor of the Scientific, Standardization Committee of the ISTH. The reproductive health of women with von Willebrand disease unresponsive to DDAVP: results of an international survey. Thromb Haemost 1995; 74: 78490.
  • 340
    Bottini E, Pareti FI, Mari D, Mannucci PM, Muggiasca ML, Conti M. Prevention of hemoperitoneum during ovulation by oral contraceptives in women with type III von Willebrand disease and afibrinogenemia: case reports. Haematologica 1991; 76: 4313.
  • 341
    Ghosh K, Mohanty D, Pathare AV, Jijina F. Recurrent haemoperitoneum in a female patient with type III von Willebrand’s disease responded to administration of oral contraceptive. Haemophilia 1998; 4: 7678.
  • 342
    Gomez A, Lucia JF, Perella M, Aguilar C. Haemoperitoneum caused by haemorrhagic corpus luteum in a patient with type 3 von Willebrand’s disease. Haemophilia 1998; 4: 602.
  • 343
    Jarvis RR, Olsen ME. Type I von Willebrand’s disease presenting as recurrent corpus hemorrhagicum. Obstet Gynecol 2002; 99: 8878.
  • 344
    Meschengieser SS, Alberto MF, Salviu J, Bermejo E, Lazzari MA. Recurrent haemoperitoneum in a mild von Willebrand’s disease combined with a storage pool deficit. Blood Coagul Fibrinolysis 2001; 12: 2079.
  • 345
    Kadir RA, Lee CA, Sabin CA, Pollard D, Economides DL. Pregnancy in women with von Willebrand’s disease or factor XI deficiency. Br J Obstet Gynaecol 1998; 105: 31421.
  • 346
    Kadir RA. Women and inherited bleeding disorders: pregnancy and delivery. Semin Hematol 1999; 36(Suppl. 4): 2835.
  • 347
    Kouides PA. Obstetric and gynaecological aspects of von Willebrand disease. Best Pract Res Clin Haematol 2001; 14: 38199.
  • 348
    Lee CA, Chi C, Pavord SR et al. The obstetric and gynaecological management of women with inherited bleeding disorders: review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors’ Organization. Haemophilia 2006; 12: 30136.
  • 349
    Mannucci PM. How I treat patients with von Willebrand disease. Blood 2001; 97: 19159.
  • 350
    Kullander S, Nilsson IM. Human placental transfer of an antifibrinolytic agent (AMCA). Acta Obstet Gynecol Scand 1970; 49: 2412.
  • 351
    Astedt B, Nilsson IM. Recurrent abruptio placentae treated with the fibrinolytic inhibitor tranexamic acid. Br Med J 1978; 1: 7567.
  • 352
    Lindoff C, Rybo G, Astedt B. Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. Thromb Haemost 1993; 70: 23840.
  • 353
    Storm O, Weber J. Prolonged treatment with tranexamic acid (Cyclocapron) during pregnancy [Danish]. Ugeskr Laeger 1976; 138: 17812.
  • 354
    Sundqvist SB, Nilsson IM, Svanberg L, Cronberg S. Pregnancy and parturition in a patient with severe Glanzmann’s thrombasthenia. Scand J Haematol 1981; 27: 15964.
  • 355
    Svanberg L, Astedt B, Nilsson IM. Abruptio placentae: treatment with the fibrinolytic inhibitor tranexamic acid. Acta Obstet Gynecol Scand 1980; 59: 12730.
  • 356
    Walzman M, Bonnar J. Effects of tranexamic acid on the coagulation and fibrinolytic systems in pregnancy complicated by placental bleeding. Arch Toxicol Suppl 1982; 5: 21420.
  • 357
    Howorka E, Olasinski R, Wyrzykiewicz T. Effect of EACA administered to female rabbits during pregnancy on the fetuses [Polish]. Patol Pol 1970; 21: 3114.
  • 358
    Kassam SH, Hadi HA, Fadel HE, Sanchez-Ramos L, Milner PF. Sickle-cell-induced hematuria in pregnancy: the current diagnostic and therapeutic approach. J Reprod Med 1984; 29: 11721.
  • 359
    Everett C. Incidence and outcome of bleeding before the 20th week of pregnancy: prospective study from general practice. BMJ 1997; 315: 324.
  • 360
    Nybo Andersen AM, Wohlfahrt J, Christens P, Olsen J, Melbye M. Maternal age and fetal loss: population based register linkage study. BMJ 2000; 320: 170812.
  • 361
    Burlingame J, McGaraghan A, Kilpatrick S, Hambleton J, Main E, Laros RK. Maternal and fetal outcomes in pregnancies affected by von Willebrand disease type 2. Am J Obstet Gynecol 2001; 184: 22930.
  • 362
    Caliezi C, Tsakiris DA, Behringer H, Kuhne T, Marbet GA. Two consecutive pregnancies and deliveries in a patient with von Willebrand’s disease type 3. Haemophilia 1998; 4: 8459.
  • 363
    Chediak JR, Alban GM, Maxey B. Von Willebrand’s disease and pregnancy: management during delivery and outcome of offspring. Am J Obstet Gynecol 1986; 155: 61824.
  • 364
    Stedeford JC, Pittman JA. Von Willebrand’s disease and neuroaxial anaesthesia. Anaesthesia 2000; 55: 12289.
  • 365
    Ross MG, Ervin MG, Novak D. Placental and fetal physiology. In: GabbeSG, NiebylJR, SimpsonJL, eds. Obstetrics: Normal and Problem Pregnancies, 4th edn. New York: Churchill Livingstone, 2002: 3762.
  • 366
    Benedetti TJ. Obstetric hemorrhage. In: GabbeSG, NiebylJR, SimpsonJL, eds. Obstetrics: Normal and Problem Pregnancies, 5th edn. New York, NY: Churchill Livingstone, 2005: 50338.
  • 367
    Kouides PA, Phatak PD, Burkart P et al. Gynaecological and obstetrical morbidity in women with type I von Willebrand disease: results of a patient survey. Haemophilia 2000; 6: 6438.
  • 368
    Gardella C, Taylor M, Benedetti T, Hitti J, Critchlow C. The effect of sequential use of vacuum and forceps for assisted vaginal delivery on neonatal and maternal outcomes. Am J Obstet Gynecol 2001; 185: 896902.
  • 369
    Edwards A, Ellwood DA. Ultrasonographic evaluation of the postpartum uterus. Ultrasound Obstet Gynecol 2000; 16: 6403.
  • 370
    Marchant S, Alexander J, Garcia J, Ashurst H, Alderdice F, Keene J. A survey of women’s experiences of vaginal loss from 24 hours to three months after childbirth (the BLiPP study). Midwifery 1999; 15: 7281.
  • 371
    Visness CM, Kennedy KI, Ramos R. The duration and character of postpartum bleeding among breast-feeding women. Obstet Gynecol 1997; 89: 15963.
  • 372
    Dahlman T, Hellgren M, Blomback M. Changes in blood coagulation and fibrinolysis in the normal puerperium. Gynecol Obstet Invest 1985; 20: 3744.
  • 373
    Sánchez-Luceros A, Meschengieser SS, Marchese C et al. Factor VIII and von Willebrand factor changes during normal pregnancy and puerperium. Blood Coagul Fibrinolysis 2003; 14: 64751.
  • 374
    Hoveyda F, MacKenzie IZ. Secondary postpartum haemorrhage: incidence, morbidity and current management. BJOG 2001; 108: 92730.
  • 375
    Lee CY, Madrazo B, Drukker BH. Ultrasonic evaluation of the postpartum uterus in the management of postpartum bleeding. Obstet Gynecol 1981; 58: 22732.
  • 376
    Ramsahoye BH, Davies SV, Dasani H, Pearson JF. Obstetric management in von Willebrand’s disease: a report of 24 pregnancies and a review of the literature. Haemophilia 1995; 1: 1404.
  • 377
    Roqué H, Funai E, Lockwood CJ. Von Willebrand disease and pregnancy. J Matern Fetal Med 2000; 9: 25766.
  • 378
    Weiss HJ. The bleeding tendency in patients with low von Willebrand factor and type 1 phenotype is greater in the presence of impaired collagen-induced platelet aggregation. J Thromb Haemost 2004; 2: 1989.
  • 379
    Kunicki TJ, Federici AB, Salomon DR et al. An association of candidate gene haplotypes and bleeding severity in von Willebrand disease (VWD) type 1 pedigrees. Blood 2004; 104: 235967 (Epub 29 June 2004).
  • 380
    Casonato A, Pontara E, Dannhaeuser D et al. Re-evaluation of the therapeutic efficacy of DDAVP in type IIB von Willebrand’s disease. Blood Coagul Fibrinolysis 1994; 5: 95964.
  • 381
    Kyrle PA, Niessner H, Dent J et al. IIB von Willebrand’s disease: pathogenetic and therapeutic studies. Br J Haematol 1988; 69: 559.
  • 382
    Mauz-Körholz C, Budde U, Kruck H, Korhölz D, Göbel U. Management of severe chronic thrombocytopenia in von Willebrand’s disease type 2B. Arch Dis Child 1998; 78: 25760.
  • 383
    Ruggeri ZM, Lombardi R, Gatti L, Bader R, Valsecchi C, Zimmerman TS. Type IIB von Willebrand’s disease: differential clearance of endogenous versus transfused large multimer von Willebrand factor. Blood 1982; 60: 14536.
  • 384
    Lopez-Fernandez MF, Blanco-Lopez MJ, Castineira MP, Batlle J. Further evidence for recessive inheritance of von Willebrand disease with abnormal binding of von Willebrand factor to factor VIII. Am J Hematol 1992; 40: 207.
  • 385
    Goudemand J, Negrier C, Ounnoughene N, Sultan Y. Clinical management of patients with von Willebrand’s disease with a VHP vWF concentrate: the French experience. Haemophilia 1998; 4(Suppl. 3): 4852.
  • 386
    Bunnell BA, Muul LM, Donahue RE, Blaese RM, Morgan RA. High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes. Proc Natl Acad Sci USA 1995; 92: 773943.
  • 387
    Blaese RM. Optimism regarding the use of RNA/DNA hybrids to repair genes at high efficiency. J Gene Med 1999; 1: 1447.
  • 388
    Taubes G. Gene therapy: the strange case of chimeraplasty. Science 2002; 298: 211620.
  • 389
    Zhang Z, Eriksson M, Falk G et al. Failure to achieve gene conversion with chimeric circular oligonucleotides: potentially misleading PCR artifacts observed. Antisense Nucleic Acid Drug Dev 1998; 8: 5316.
  • 390
    Conti M, Mari D, Conti E, Muggiasca ML, Mannucci PM. Pregnancy in women with different types of von Willebrand disease. Obstet Gynecol 1986; 68: 2825.
  • 391
    Todd RF III, Gitlin SD, Burns LJ, Committee on Training Programs. Subspeciality training in hematology and oncology, 2003: results of a survey of training program directors conducted by the American Society of Hematology. Blood 2004; 103: 43838 (Epub 5 February 2004).
  • 392
    Department of Health and Human Services. Clinical Hematology Research Career Development Program [Homepage on the Internet]. Bethesda, MD: Department of Health and Human Services. Available at: http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-06-006.html (last accessed 23.01.2008).
  • 393
    National Hemophilia Foundation. The National Hemophilia Foundation Clinical Fellowship Program. New York: National Hemophilia Foundation, c2006. Available at: http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=247&contentid=430&rptname=research
  • 394
    Woods AI, Meschengieser SS, Blanco AN et al. Clinical features and laboratory patterns in a cohort of consecutive Argentinian patients with von Willebrand’s disease. Haematologica 2001; 86: 4207.
  • 395
    Ziv O, Ragni MV. Bleeding manifestations in males with von Willebrand disease. Haemophilia 2004; 10: 1628.
  • 396
    Piot B, Sigaud-Fiks M, Huet P, Fressinaud E, Trossaert M, Mercier J. Management of dental extractions in patients with bleeding disorders. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002; 93: 24750.
  • 397
    Marder VJ, Mannucci PM, Firkin BG, Hoyer LW, Meyer D. Standard nomenclature for factor VIII and von Willebrand factor: a recommendation by the International Committee on Thrombosis and Haemostasis. Thromb Haemost 1985; 54: 8712.
  • 398
    Mazurier C, Rodeghiero F, von Willebrand Factor Subcommittee of the Scientific, Standardization Committee of the International Society on Thrombosis, Haemostasis. Recommended abbreviations for von Willebrand factor and its activities. Thromb Haemost 2001; 86: 712.
  • 399
    Castaman G, Novella E, Castiglia E, Eikenboom JC, Rodeghiero F. A novel family with recessive von Willebrand disease due to compound heterozygosity for a splice site mutation and a missense mutation in the von Willebrand factor gene. Thromb Res 2002; 105: 1358.
  • 400
    Zhang Z, Lindstedt M, Blomback M, Anvret M. Effects of the mutant von Willebrand factor gene in von Willebrand disease. Hum Genet 1995; 96: 38894.
  • 401
    Inbal A, Kornbrot N, Zivelin A, Shaklai M, Seligsohn U. The inheritance of type I and type III von Willebrand’s disease in Israel: linkage analysis, carrier detection and prenatal diagnosis using three intragenic restriction fragment length polymorphisms. Blood Coagul Fibrinolysis 1992; 3: 16777.
  • 402
    Nichols WC, Lyons SE, Harrison JS, Cody RL, Ginsburg D. Severe von Willebrand disease due to a defect at the level of von Willebrand factor mRNA expression: detection by exonic PCR-restriction fragment length polymorphism analysis. Proc Natl Acad Sci U S A 1991; 88: 385761.
  • 403
    Gill JC, Ewenstein BM, Thompson AR, Mueller-Velten G, Schwartz BA, Humate-P Study Group. Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy. Haemophilia 2003; 9: 68895.
  • 404
    Kingman CE, Kadir RA, Lee CA, Economides DL. The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders. BJOG 2004; 111: 14258.
  • 405
    Leissinger C, Becton D, Cornell C Jr, Cox Gill J. High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia 2001; 7: 25866.
  • 406
    Rodeghiero F, Castaman G, Mannucci PM. Prospective multicenter study on subcutaneous concentrated desmopressin for home treatment of patients with von Willebrand disease and mild or moderate hemophilia A. Thromb Haemost 1996; 76: 6926.
  • 407
    Mohri H. High dose of tranexamic acid for treatment of severe menorrhagia in patients with von Willebrand disease. J Thromb Thrombolysis 2002; 14: 2557.